Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: turning into a bad investment

when the patents expire and the look back period is all that's left ? As it is, those 400 on notice are only liable for infringing products since 2005 at the most.

Starting today, a cumulative dividend to stockholders of just 30 cents during all future licensing and Prosecution, would mean a payout by PTSC of $120,000,000. That amount alone would inturn necessitate a total license fee recovery to PDS of at least $350,000,000 ,and significantly more if the recovery amount requires litigation; and large fees will. This is the dividend view of ROI we need to try to calculate if we plan to hold the stock till the very end when there is no further legal right to demand a fee for using the MMP technology.

If we want to sell, what will make anyone want to buy our PTSC stock as 2015 approaches and potential licensing fees get limited and begin to dry up ? The new buyers will likely do an analysis something like the one above, and that dividend recovery window guesstimation will be what determines how much they'll be willing to pay to own the stock.

To want to buy the stock, future Shareholders need to know there is revenue potential for PTSC after the MMP patents dry up beginning in 2015, less that 2 years away.

If future investors don't know or think there is, this will seriously impact our ability to sell our stock at anything other than these Pixi stick prices.

Cliff, act like a hands-on CEO, take the bull by the horns and address the concerns of this compay's owners with an Open Letter to Shareholders about the future of our company; NOW

Share
New Message
Please login to post a reply